Chimeric influenza vaccines
AssigneeAcademia Sinica
InventorsChi-Huey Wong, Hsin-Yu Liao, Shih-Chi Wang, Yi-An Ko, Kuo-I Lin, Che Ma, Ting-Jen Cheng
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a chimeric influenza virus hemagglutinin (HA) polypeptide, comprising one or more stem domain sequence, each having at least 60% homology with a stem domain consensus sequence of H1 subtype HA (H1 HA) and/or H5 subtype HA (H5 HA), fused with one or more globular head domain sequence, each having at least 60% homology with a globular head domain consensus sequence of H1 subtype HA (H1 HA) or H5 subtype HA (H5 HA).
Claims9
An immunogenic composition comprising a fully glycosylated chimeric influenza virus hemagglutinin (HA) polypeptide and an adjuvant;
- wherein the fully glycosylated chimeric influenza virus HA polypeptide comprising an amino acid sequence of SEQ ID NO:
- 4;
- wherein the fully glycosylated chimeric influenza virus HA polypeptide has complex type N-glycans at N28, N40, N171, N182, N292, N303, and N497;
- and
- wherein the adjuvant is selected from the group consisting of Al(OH)3, AlPO4, an analog of α-galactosylceramide (α-GalCer), squalene and QS21.
Dependencies are inferred from the claim text.